I certainly messed up on timing as I sold a small portion of my IMGN holdings yesterday to acquire more NWBO which I believe could explode on unblinding the Phase 3 Trial they've had going for over a decade. No doubt the trial failed to meet original goals, which were PFS based, but 4 years after the last GBM patient entered the trial, it's thought that somewhere between 60 and 80 some patients remain alive. Survival is what should result in approval, statistically at four year on the SOC perhaps 15 patients would have been expected to be alive, clearly more are living on the vaccine, and the company is working to get a new SAP before unblinding.
As for IMGN, abstracts for IMGN632 are due out tomorrow morning, today's action could reflect what's anticipated, and clearly I'm still thrilled to see it moving up, just wished I'd waited before selling some. I still hold substantial Jan $4 calls, and if this move continues I'll add far more stock to my portfolio then I sold yesterday.
Gary |
